Last reviewed · How we verify
NP10679
At a glance
| Generic name | NP10679 |
|---|---|
| Sponsor | Neurop Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers (PHASE1)
- Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NP10679 CI brief — competitive landscape report
- NP10679 updates RSS · CI watch RSS
- Neurop Inc. portfolio CI